Use our account feature to register for a free CLI account. Your new account will allow you to bookmark and organize articles and research for easy reference later - making it simple to keep track of the research that's important to you!
Register / Sign in
Search Icon
Search Icon
Use our account feature to register for a free CLI account. Your new account will allow you to bookmark and organize articles and research for easy reference later - making it simple to keep track of the research that's important to you!
Register / Sign in
close-panel

Charlotte Lozier Institute

Phone: 202-223-8073
Fax: 571-312-0544

2776 S. Arlington Mill Dr.
#803
Arlington, VA 22206

Get Notifications

Sign up to receive email updates from Charlotte Lozier Institute.

This field is for validation purposes and should be left unchanged.

Become A Defender of Life

Your donation helps us continue to provide world-class research in defense of life.

DONATE

Charlotte Lozier Institute

Phone: 202-223-8073
Fax: 571-312-0544

2776 S. Arlington Mill Dr.
#803
Arlington, VA 22206

Life & the LawAbortionAbortion Drugs

Testimony of Monique Chireau Wubbenhorst, M.D. Before the Senate HELP Committee

On January 14, 2026, the Senate Health, Education, Labor, and Pensions (HELP) Committee held a hearing on “Protecting Women: Exposing the Dangers of Chemical Abortion Drugs.”

Dr. Monique Chireau Wubbenhorst, a board‑certified obstetrician‑gynecologist with more than three decades of experience, testified at the hearing. She described the physical and mental risks associated with abortion drugs, referencing research from CLI.

Watch Dr. Wubbenhorst’s testimony below.

Latest Posts

October 6, 2026 A magnifying glass rests on three wooden blocks that spell out FDA, symbolizing a review of the REMS modification. A Critical Analysis of the FDA’s 2021 Mifepristone REMS Modification Rationale Review October 6, 2026 Ultrasound image showing the side profile of a human baby Inside The Government Decision That Opened Up Abortion Pill Floodgates October 6, 2026 A sign for the FDA featuring the agency’s logo and circular seals in front of a brick government building, where clinical guidance for mifepristone REMS is often determined. Unintended Consequences of the FDA’s 2021-2023 Risk Evaluation and Mitigation Strategy (REMS) Changes to Mifepristone

You Might Also Be Interested In

A magnifying glass rests on three wooden blocks that spell out FDA, symbolizing a review of the REMS modification.

A Critical Analysis of the FDA’s 2021 Mifepristone REMS Modification Rationale Review

October 6, 2026
Please login to bookmark Close
A sign for the FDA featuring the agency’s logo and circular seals in front of a brick government building, where clinical guidance for mifepristone REMS is often determined.

Unintended Consequences of the FDA’s 2021-2023 Risk Evaluation and Mitigation Strategy (REMS) Changes to Mifepristone

October 6, 2026
Please login to bookmark Close
A person in a white shirt dropping an abortion ballot into a white box against a yellow background.

Abortion on the Ballot in November

October 2, 2026
Please login to bookmark Close

Become A Defender of Life

Your donation helps us continue to provide
world-class research in defense of life.

BECOME A PARTNER
cta-image